“The biologics stakes are increasing rapidly. All of big pharma is investing in this,” said Brian O’Reilly, one of three partners joining Kilpatrick from DLA Piper.
October 15, 2020 at 01:19 PM
1 minute read
staff reporter
The original version of this story was published on The American Lawyer
Kilpatrick Townsend & Stockton has recruited a five-lawyer IP litigation team focused on high-stakes biopharma patent disputes.
Brian O’Reilly, one of three partners joining Kilpatrick from DLA Piper, said they made the move “to prepare for bet-the-company cases as disputes increase over biologic patents.”
Presented by BigVoodoo
The Daily Report is honoring those attorneys and judges who have made a remarkable difference in the legal profession.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
(l-r) Brian O’Reilly, April Isaacson and Mike Furrow, with Kilpatrick Townsend & Stockton. Courtesy photos
